Drug Type Small molecule drug |
Synonyms BPM31510T, Co-Enzyme Q10, Coenxyme Q10 + [26] |
Target |
Action modulators, stimulants |
Mechanism HMOX1 modulators(Heme oxygenase 1 modulators), NOS2 stimulants(Nitric oxide synthase, inducible stimulants), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (27 Jul 1976), |
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (Japan) |
Molecular FormulaC59H90O4 |
InChIKeyACTIUHUUMQJHFO-UPTCCGCDSA-N |
CAS Registry303-98-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01065 | Ubidecarenone |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Heart Failure | Japan | 27 Jul 1976 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 2 | United States | 30 Jan 2022 | |
| Squamous Cell Carcinoma | Phase 2 | - | 01 Mar 2008 | |
| Superficial basal cell carcinoma | Phase 2 | United States | 01 Mar 2008 | |
| Multiple System Atrophy | Phase 2 | Japan | - | |
| Glioblastoma | Phase 1 | United States | 30 Jan 2022 | |
| Brain Cancer | Phase 1 | United States | 01 Oct 2013 | |
| Brain metastases | Phase 1 | United States | 01 Oct 2013 | |
| Colorectal Cancer | Phase 1 | United States | 01 Oct 2013 | |
| Glaucoma | Preclinical | Spain | 20 Jan 2026 | |
| Acute Kidney Injury | Preclinical | Brazil | 23 Oct 2018 |
Not Applicable | - | 47 | dvfteyehfb(njzjolejzh) = While the overall incidence and severity distribution of diarrhea did not significantly differ, a trend toward reduced occurrence of Grade 2 diarrhea was observed in the rCoQ10 group. tkuqaoaudo (padmxowjlt ) View more | Negative | 21 Apr 2026 | ||
Placebo | |||||||
Phase 3 | 58 | ehrnkszssf(assfqhxnsb) = uxssaoodar vjsjrjknbl (aqyzyslykt ) View more | Positive | 15 Apr 2026 | |||
Placebo | ehrnkszssf(assfqhxnsb) = vcmcdpyvsq vjsjrjknbl (aqyzyslykt ) View more | ||||||
Phase 3 | - | 100 | qbkcywkuuy(udfakcphjc): P-Value = 0.001 View more | Positive | 01 Mar 2026 | ||
Phase 4 | - | 70 | rsbonjbxgy(uwemfjfqhs) = ktylrszrmx xwtejliwhc (jaseqgbfhc ) View more | Positive | 02 Sep 2025 | ||
(Placebo) | gsdzealqji(fapcakfcrg) = qvcyljtcgk uiylwkvnte (ofewhwqjuk ) View more | ||||||
Phase 3 | 100 | (Ubiquinol) | eshtrhszrq(pdojjhvykr) = hadjrbnypa xvtumavxts (msrrkdmwvc, 11.1) View more | - | 15 Feb 2023 | ||
Placebo (Placebo) | eshtrhszrq(pdojjhvykr) = pkjvezaafk xvtumavxts (msrrkdmwvc, 10.1) View more | ||||||
Phase 2 | 121 | uogrcbqxwb(aqdizbrvxc): mean difference = 0.01 (95% CI, -0.02 to 0.04), P-Value = 0.45 View more | Negative | 02 Nov 2022 | |||
(Placebo) | |||||||
Phase 2 | 216 | Placebo ubiquinol capsules and d-ribose powder | viwyukwhal(fbpslhgvzm) = uyztydivcf ywqugiwoas (qmnkrrhrph ) View more | Positive | 01 Aug 2022 | ||
Ubiquinol capsules (600 mg/d) and placebo d-ribose powder | viwyukwhal(fbpslhgvzm) = qigpzcgqgs ywqugiwoas (qmnkrrhrph ) View more | ||||||
Phase 2 | 216 | Placebo powder (Placebo Only) | iwshsoewvi(xthcddsjin) = tblcgmtkrb rurheywyix (hqgtowjuqi, 24.04) View more | - | 03 Mar 2022 | ||
Placebo powder+CoQ10 (CoQ10 Only) | iwshsoewvi(xthcddsjin) = uzvzxosova rurheywyix (hqgtowjuqi, 18.61) View more | ||||||
Phase 2 | 48 | Ensure+Ubiquinol | gfmdesgyrt(qfbmuohyro) = uprjilojak typhcruoem (nuavzgvdoh, olysaigtwr - bmlterlyih) View more | - | 15 Feb 2021 | ||
Phase 1 | 12 | BPM31510 + Vitamin K | kkdrpeizqt(rwnyjhvmvt) = linear with dose escalation cttbdnjynj (mstyqvtlmd ) View more | - | 25 May 2020 |





